Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476]
1 Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe.
2 Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe. Electronic address: nkiyota@med.kobe-u.ac.jp.
3 Cancer Treatment Center, Kansai Medical University Hospital, Hirakata.
4 Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama.
5 Department of Medical Oncology, Hyogo Cancer Center, Akashi.
6 Department of Head and Neck Surgery, Miyagi Cancer Center, Natori.
7 Department of Head and Neck Oncology, Miyagi Cancer Center, Natori.
8 Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
9 Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe; Cancer Center, Kobe University Hospital, Kobe.